Time to castration-resistant prostate cancer (CRPC) by PSMA PET/CT bone lesion cohort at initial staging. (IMAGE)

Society of Nuclear Medicine and Molecular Imaging

Time to castration-resistant prostate cancer (CRPC) by PSMA PET/CT bone lesion cohort at initial staging.

Caption

Figure 1. Time to castration-resistant prostate cancer (CRPC) by PSMA PET/CT bone lesion cohort at initial staging. Kaplan Meier curves showing time to CRPC by bone lesion cohort on PSMA PET/CT at initial staging. Patients with even one to five PSMA-detected bone metastases progressed to treatment-resistant cancer significantly faster than patients with no bone spread (p < 0.0001). Compared to patients whose PSMA PET showed no distant metastases, patients with bone lesions had more than five times the risk of developing castration-resistant diseases even though all patients with bone lesions received systemic therapy intensification.

Credit

Image courtesy of SNMMI.

Usage Restrictions

Please give appropriate credit.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.